These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 28659338)
21. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405 [TBL] [Abstract][Full Text] [Related]
22. Acute myeloid leukemia in the vascular niche. Cogle CR; Bosse RC; Brewer T; Migdady Y; Shirzad R; Kampen KR; Saki N Cancer Lett; 2016 Oct; 380(2):552-560. PubMed ID: 25963886 [TBL] [Abstract][Full Text] [Related]
23. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259 [TBL] [Abstract][Full Text] [Related]
24. Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. Lueck SC; Russ AC; Botzenhardt U; Schlenk RF; Zobel K; Deshayes K; Vucic D; Döhner H; Döhner K; Fulda S; Bullinger L Oncotarget; 2016 Aug; 7(31):49539-49551. PubMed ID: 27385100 [TBL] [Abstract][Full Text] [Related]
25. Adhesion Molecules, Stem Cells, and the Microenvironment in Acute Myeloid Leukemia. Brower V J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 27038119 [No Abstract] [Full Text] [Related]
26. Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways. Nagai T; Ohmine K; Fujiwara S; Uesawa M; Sakurai C; Ozawa K Leuk Res; 2010 Aug; 34(8):1057-63. PubMed ID: 20071026 [TBL] [Abstract][Full Text] [Related]
27. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Maiso P; Colado E; Ocio EM; Garayoa M; Martín J; Atadja P; Pandiella A; San-Miguel JF Leukemia; 2009 Dec; 23(12):2265-74. PubMed ID: 19812608 [TBL] [Abstract][Full Text] [Related]
28. Curcumin induces apoptosis by inhibiting BCAT1 expression and mTOR signaling in cytarabine‑resistant myeloid leukemia cells. Tseng YH; Yang RC; Chiou SS; Shieh TM; Shih YH; Lin PC Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34109436 [TBL] [Abstract][Full Text] [Related]
29. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia. Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658 [TBL] [Abstract][Full Text] [Related]
30. Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment. Becker PS ScientificWorldJournal; 2012; 2012():856467. PubMed ID: 22346731 [TBL] [Abstract][Full Text] [Related]
32. A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. Bolandi SM; Pakjoo M; Beigi P; Kiani M; Allahgholipour A; Goudarzi N; Khorashad JS; Eiring AM Cells; 2021 Oct; 10(11):. PubMed ID: 34831055 [TBL] [Abstract][Full Text] [Related]
33. Targeting the bone marrow microenvironment in acute leukemia. Karantanou C; Godavarthy PS; Krause DS Leuk Lymphoma; 2018 Nov; 59(11):2535-2545. PubMed ID: 29431560 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of resistance and therapeutic prospect of leukemia mediated by signaling pathway in bone marrow microenvironment. Zhang LP; Zhang MY; Liu WJ Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6419-6428. PubMed ID: 31378880 [TBL] [Abstract][Full Text] [Related]
35. Role of Microenvironment in Resistance to Therapy in AML. Tabe Y; Konopleva M Curr Hematol Malig Rep; 2015 Jun; 10(2):96-103. PubMed ID: 25921386 [TBL] [Abstract][Full Text] [Related]
36. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL. Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392 [TBL] [Abstract][Full Text] [Related]
37. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505 [TBL] [Abstract][Full Text] [Related]
39. The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations. Zhang W; Borthakur G; Gao C; Chen Y; Mu H; Ruvolo VR; Nomoto K; Zhao N; Konopleva M; Andreeff M Cancer Res; 2016 Mar; 76(6):1528-37. PubMed ID: 26822154 [TBL] [Abstract][Full Text] [Related]
40. A three-dimensional Bray LJ; Binner M; Körner Y; von Bonin M; Bornhäuser M; Werner C Haematologica; 2017 Jul; 102(7):1215-1226. PubMed ID: 28360147 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]